Table 3 . Ongoing clinical trials with the application of combined ICI-FMT therapy in cancer patients (www.clinicaltrials.gov) 74 .
| NCT number | Type of cancer | Number of patients | Intervention | Stage |
|---|---|---|---|---|
| NCT04521075 | Melanoma; CPCNP | 50 | FMT + Nivolumab | Phase 2 |
| NCT04988841 | Melanoma | 60 | MaaT013 + Ipilimumab + Nivolumab versus placebo + Ipilimumab + Nivolumab | Phase 2 |
| NCT03341143 | Melanoma | 20 | FMT + Pembrolizumab | Phase 2 |
| NCT03772899 | Melanoma | 20 | FMT + Pembrolizumab/Nivolumab | Phase 1 |
| NCT03353402 | Melanoma | 40 | FMT + ICI | Phase 1 |
| NCT04577729 | Melanoma | 60 | Allogeneic FMT + ICI versus autologous FMT + ICI | Not applicable |
FMT: fecal microbiota transplantation; ICI: immune checkpoint inhibitor. Source: Authors (2023).